SHUFTI-PRO
8.2.2023 06:50:44 CET | Business Wire | Press release
Pioneer of first-ever on-premises IDV solutions, Shufti Pro, has announced the launch of its risk assessment and eIDV services to help global businesses fight identity fraud and financial crimes, and meet the ever-evolving KYC/AML regulatory landscape.
Risk Assessment Solution - is the purposely built tool to help businesses identify risks associated with their globally diverse client base. Shufti Pro’s custom-built risk-scoring solution adapts to the interests of organisations whilst addressing every possible risk factor to safeguard businesses from financial crimes, reputational damages, and regulatory sanctions. It ensures enterprises make informed decisions by evaluating customer risk factors through custom questionnaires and fraud prevention data points, further examined by the Shufti Pro’s risk intelligence profiling engines (a database of over 10B ID elements).
eIDV Service - eIDV is the process of verifying customers through a government-issued unique identifier number. It works similar to the KYC process, asides from the requirement of paper-based document uploads provided by the customer. Shufti Pro’s eIDV matches the clients’ data, such as name, DoB, and SSN, against multiple databases and provides unparalleled security. The digitisation of the modern world shows us to be moving away from paper IDs, towards completely electronic forms due to enhanced privacy, fraud prevention and the elevation of user experience. Such changes will ensure customer onboarding will be easier, more accurate, cater to global customers and effectively reduce client abandonment rates.
“As a global IDV service provider, Shufti Pro continuously innovates to meet an increasingly varied and diverse range of regulatory compliance requirements for our customers,” said Victor Fredung, CEO of Shufti Pro. “We are dedicated to providing solutions that address the changing needs of our global clientele and the wider general market – both at the point of onboarding and beyond, and I am pleased to share that risk assessment and eIDV services do just that.”
Shufti Pro recently introduced an array of new features, such as SSO implementation, duplicate account verification, and more to strengthen the suite of its IDV products. Last year, the company secured $20M in Series A funding to accelerate its international expansion, enhance its IDV solutions and expand its compliance suite.
Global organisations looking for an IDV partner can contact Shufti Pro here.
About Shufti Pro
Shufti Pro is a leading IDV service provider offering KYC, KYB, KYI, AML, biometric verification, and OCR solutions and accelerating trust worldwide. It has six international offices and has launched a suite of 17 complimentary IDV products and solutions. With the ability to automatically verify 9000+ ID documents in 150+ languages, Shufti Pro proudly serves customers in 230+ countries and territories.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230207005763/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM and Deutsche Bahn Demonstrate Quantum Algorithm for Railway Scheduling on Real Operational Data20.7.2026 08:00:00 CEST | Press release
A hybrid quantum-classical algorithm, executed end to end on IQM hardware, produced feasible schedules with Deutsche Bahn, the German rail operator, using a real operational dataset of 190 trips across five German cities. The approach runs on today’s hardware and is designed to improve automatically as quantum processors scale, offering enterprises a model for extracting value now, ahead of fault-tolerant computing. The collaboration reflects IQM’s push into enterprise adoption. The company has sold 24 quantum computers worldwide and listed on the Nasdaq Global Select Market and Nasdaq Helsinki in July 2026 under the ticker IQMX. IQM Quantum Computers (Nasdaq: IQMX), a global leader in full-stack superconducting quantum computers, today published the results of a research collaboration with Deutsche Bahn, Europe’s largest rail operator, exploring how quantum computing can improve railway scheduling. This press release features multimedia. View the full release here: https://www.busines
Galderma Launches Alastin® in Japan and Key Markets Across Asia Pacific, Expanding Its Footprint in the Region20.7.2026 07:00:00 CEST | Press release
Galderma launches Alastin, its premium regenerative skincare brand into Japan, Singapore, South Korea and Taiwan The Japan and Asia Pacific (JPAC) region is among the fastest‑growing markets globally for medical aesthetics and dermatological skincare, driven by rising adoption of minimally invasive procedures and an increased focus on skin quality, which are accelerating demand for innovative, science‑based skincare solutions such as Alastin1,2 These launches reflect Galderma’s ongoing growth across the JPAC region and long‑term commitment to advancing regenerative skincare Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the launch of Alastin – its premium regenerative skincare brand – across the JPAC region. The brand recently launched in Taiwan, will soon launch in Japan, and has received approval to launch in Singapore and South Korea, with planned market introduction in September and November, respectively. This expansion follows Alastin’s recent la
Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers17.7.2026 19:10:00 CEST | Press release
Rapid oral presentations will highlight new Phase 1 data across Incyte’s solid tumor portfolioBoth INCB161734, an investigational, potent, selective and orally bioavailable KRAS G12D inhibitor, and INCA338901, a TGFβR2×PD-1 bispecific antibody, are being evaluated in ongoing Phase 3 programs as first-line treatments for patients with advanced pancreatic ductal adenocarcinoma (PDAC) and microsatellite stable (MSS) colorectal cancer, respectively Incyte (Nasdaq:INCY) today announced that it will highlight data from several programs in its oncology portfolio in six presentations at the European Society of Medical Oncology (ESMO) Congress 2026, being held October 23 - 27, 2026, in Madrid. “The data at ESMO will further illustrate Incyte’s commitment to advancing innovation for patients with cancer,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "Among the presentations are important updates from our KRAS G12D inhibitor in advanced pancreatic ca
STL Expands Its Optical Connectivity Portfolio in the US with the CONCAT Solution17.7.2026 14:24:00 CEST | Press release
STL Optical Connectivity NA, LLC, (STLOC), a U.S. subsidiary of STL (Sterlite Technologies Ltd.) [NSE: STLTECH], a leading connectivity solutions provider for AI-ready digital infrastructure, today announced that it launched its new advanced FTTH solution, CONCAT, after successfully completing field trials on the networks of one of the largest telecom service providers in the United States. Following successful field validation, CONCAT is now available to digital infrastructure providers seeking faster fiber rollouts with reduced deployment complexity and labor. It enables up to 71% in labor cost savings by eliminating most field splicing through factory-assembled, pre-connectorized fiber segments that deliver plug-and-play installation. CONCAT simplifies fiber deployment by shifting critical fiber preparation and termination into a controlled manufacturing environment ensuring consistent quality, faster installation, and lower operational risk in the field. CONCAT solution is ideal fo
Aqemia and Sanofi Expand Their Research Collaboration17.7.2026 12:30:00 CEST | Press release
A new target nomination and a milestone payment mark the next step of the multi-year partnership first announced in December 2023 Aqemia, the drug invention company combining generative AI and quantum-inspired physics to invent small molecule drugs, today announced the expansion of its multi-year research collaboration with the global pharmaceutical company, Sanofi. The expansion is marked by the nomination of a new therapeutic target and an additional payment. The collaboration, first announced in December 2023, makes Aqemia eligible to receive up to a total of $140 million in upfront and milestone payments across programs. It spans the drug discovery journey from the identification of the very first hits to the selection of a development candidate. Aqemia leverages Qemi, its proprietary physics-based generative AI platform, to design novel molecules addressing Sanofi’s targets of choice, working in close collaboration with Sanofi scientific teams. Sanofi leads wet lab research, devel
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom